Why Gentrack, Monash IVF, Pro Medicus, and Qube shares are racing higher today

The S&P/ASX 200 Index (ASX: XJO) has returned to form and is on course to start the week with a solid gain. In afternoon trade, the benchmark index is up 1.2% to 8,515.2 points.

Four ASX shares that are rising more than most today are listed below. Here’s why they are climbing today:

Gentrack Group Ltd (ASX: GTK)

The Gentrack share price is up 22% to $8.10. This follows the release of the airport and utilities software provider’s FY 2025 results this morning. Gentrack delivered an 8% increase in revenue to NZ$230.2 million and an 18% jump in EBITDA to NZ$27.8 million for the 12 months. And while no firm guidance was given, management reiterated its mid-term target of more than 15% compound annual revenue growth and an EBITDA margin of 15%–20%.

Monash IVF Group Ltd (ASX: MVF)

The Monash IVF share price is up 40% to 85.5 cents. Investors have been buying this fertility treatment company’s shares after it received and rejected “an opportunistic, unsolicited, conditional and non- binding indicative proposal” from a consortium comprising Genesis Capital and Washington H. Soul Pattinson and Co Ltd (ASX: SOL). The indicative cash price offered to shareholders under the proposal was $0.80 per share. However, “the Board has considered the Proposal including with the assistance of its financial and legal advisers and unanimously determined that the Proposal materially undervalues Monash IVF and is not in the best interest of the Company’s shareholders as a whole.”

Pro Medicus Ltd (ASX: PME)

The Pro Medicus share price is up 3.5% to $260.59. This morning, the health imaging technology company revealed that it has signed three new contracts with a combined minimum contract value of $29 million. These contracts will be fully cloud-deployed and are planned to be completed within the next six months. Pro Medicus’ founder and CEO, Dr Sam Hupert, said: “They comprise a children’s hospital, a cancer center, and a physician-owned and run regional healthcare provider. This diversity reinforces our belief that our product is ideally suited to virtually all segments of the market, from smaller groups all the way through to some of the largest IDN’s and academic medical centers in the US.”

Qube Holdings Ltd (ASX: QUB)

The Qube share price is up almost 18% to $4.79. This has been driven by news that the logistics solutions company has received a takeover offer from Macquarie Group Ltd (ASX: MQG). The Macquarie Asset Management (MAM) business is offering $5.20 per share for Qube. The company’s chair, John Bevan, said: “The proposal from Macquarie Asset Management is a reflection of the strength of Qube’s business model and our assets, and the quality of our people and culture. We look forward to continuing to engage constructively in the best interests of our shareholders.”

The post Why Gentrack, Monash IVF, Pro Medicus, and Qube shares are racing higher today appeared first on The Motley Fool Australia.

More reading

• Qube shareholders sitting pretty after Macquarie takeover bid launched
• Pro Medicus shares charge higher on big news
• Why is this ASX 300 tech stock rocketing 21% today?
• This Aussie fertility company has rejected a takeover bid from private equity
• Macquarie tips 54% upside for this beaten down ASX All Ords healthcare stock

Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Gentrack Group, Macquarie Group, and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Gentrack Group, Macquarie Group, and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.